BioCentury
ARTICLE | Clinical News

Nalbuphine ER: Phase II/III started

July 21, 2014 7:00 AM UTC

Trevi began a double-blind, placebo-controlled, international Phase II/III trial to evaluate 60 and 120 mg oral Nalbuphine ER twice daily for 6 weeks in 360 hemodialysis patients with moderate to seve...